NEW YORK, June 14, 2022 /PRNewswire/ -- According to the recent market research study published by P&S Intelligence, the revenue of the anti-VEGF therapeutics market will increase from $12,178.0 million in 2021 at a compound annual growth rate of 1.4% from 2021 to 2030, to touch $13,812.6 million by 2030. The development of the industry is mainly driven by the approvals of the FDA to a number of drug candidates, accompanied by R&D activities.
Eylea held the largest share in the anti-VEGF therapeutics market, in excess of 60%, in the year 2021, a satiation that is not predicted to alter in the years to come. This is mainly because of the continuous R&D on this drug. For example, Regeneron is undertaking a study to find out if an 8mg dosage can be more helpful for wet AMD patients than the presently approved 2mg dose.
Get the sample pages of this report at: https://www.psmarketresearch.com/market-analysis/anti-vascular-endothelial-growth-factor-therapeutics-market/report-sample
The most-significant anti-VEGF medication application is AMD, with this disease capturing approximately 61% share in 2021. About around 6.20 million patients who are 50 years of age or older suffered from MSVI, while 2 million people were completely blind because of AMD, and in 2020, at the global level. Though, the age-standardized occurrence of blindness caused by AMD witnessed an over 20% drop from 2000 to 2020 because of the growing consciousness and rising anti-VEGF medicine acceptance.
Further, the use of these drugs for the treatment of DR is likely to observe the highest compound annual growth rate from 2021 to 2030, because of the increasing occurrences of this condition worldwide. In excess of 100 million grown-ups had DR in the year 2020, and this number is likely to increase to over 150 million by 2045.
Regional Analysis of Anti-VEGF Therapeutics Market
- The anti-VEGF therapeutics market of North America occupied the largest share, of approximately 65%, in the year 2021. It is credited to the developments in the healthcare setup, technical progressions, proactive actions of the government, increase in the awareness of consumers, and a surge in the prevalence of ophthalmic diseases.
- Canada has predicted to observe momentous development, of 1.5%, in the coming years in the industry, because of the approvals to several anti-VEGF candidates.
- The APAC market is predicted to witness a growth rate of about 2% throughout 2021-2030. Sales licensing agreements among businesses are the main aspect driving the industry growth.
Browse detailed report on Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Size, Share, Key Players and Regional Forecast, 2030
Recently, major players in the anti-VEGF therapeutics market have actively taken part in drug R&D and marketing. For example, in February 2022, Kodiak Sciences Inc. created an anti-VEGF antibody biopolymer conjugate for patients suffering from DME and finished patient registrations for its GLEAM and GLIMMER phase III clinical trials.
Anti-VEGF Therapeutics Market Segmentation Analysis
By Product
- Eylea
- Lucentis
- Beovu
By Disease
- Macular Edema
- Diabetic Retinopathy
- Retinal Vein Occlusion
- Age-Related Macular Degeneration
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa
- Saudi Arabia
- South Africa
- U.A.E.
Browse More Related Reports
Global Age-Related Macular Degeneration Market Size, Share, and Growth Forecast Report
Global Wet Age-Related Macular Degeneration Market Size, Share, and Growth Forecast Report
Global Contact Lenses Market Size, Share, and Growth Forecast Report
Global Ocular Implants Market Size, Share, and Growth Forecast Report
About P&S Intelligence
P&S Intelligence provides market research and consulting services to a vast array of industries across the world. As an enterprising research and consulting company, P&S believes in providing thorough insights on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness. P&S keeps the interest of its clients at heart, which is why the insights we provide are both honest and accurate. Our long list of satisfied clients includes entry-level firms as well as multi-million-dollar businesses and government agencies.
Contact:
Prajneesh Kumar
P&S Intelligence
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Follow Us: LinkedIn Twitter
Logo: https://mma.prnewswire.com/media/1224988/P_and_S_Intelligence_Logo.jpg
